Yes, $15 is easily a realistic pps if the AS FDA 1, 2 and 3 are very positive. This also assumes a really good B for OM deal, much better than the AS. This will be harder as the results were good, not great. This also assumes that there will be deals all along the IBS, UC and Crohn's spectrum. Again, imo this could net IPIX more than a few dollars in deals or in successful IPIX- sponsored tests. And K, any successful FDA 2b will be worth a few dollars itself, any FDA 3s for K will add lots of dollars. So yes, if this all comes through $15 is reasonable territory, as is $7 or $8 or more. However, as other wiser posters have noted, a $1 would be a reasonable (though hard to attain) pps after an OM deal, and of course we have not even seen that as yet. I haven't added B for ABSSSI, which would could actually move ahead on just the IPIX funding if most of the pie in the sky I have mentioned comes true. Though, in reality I do expect government action in the next couple of years that should cover the new class of antibiotics that B typifies. Ok, what are the odds that all of the actions necessary to hit these lofty $ levels will come to fruition. All I can say is the odds are very high against, but certainly not impossible. Good stock for long term investors (at these bargain basement pps levels) or for shorter term, degenerate gamblers. To date, it has been best for shorts of any variety. Happy New year guys.
News 
Market Data 
Discover 
AI
